drugset
drugset / Trial / NCT01826474

Phase IIb Study of PRO045 in Subjects With Duchenne Muscular Dystrophy

NCT01826474 ↗

Phase 1/2 Terminated 15 enrolled BioMarin Pharmaceutical
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to see whether PRO045 is safe and effective to use as medication for Duchenne Muscular Dystrophy (DMD) patients with a mutation around location 45 in the DNA for the dystrophin protein.

Timeline

Start
2013-01
Primary completion
2016-08-31
Completion
2016-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject PRO045 Unknown 0.15 mg/kg Subcutaneous
Subject PRO045 Unknown 1 mg/kg Subcutaneous
Subject PRO045 Unknown 3 mg/kg Subcutaneous
Subject PRO045 Unknown 6 mg/kg Subcutaneous
Subject PRO045 Unknown 9 mg/kg Subcutaneous

Indications

Duchenne muscular dystrophy